The New Era of Epithelium-targeted Drug Development

被引：0

作者：

Shimizu, Yoshimi ^{[1
]}

Nagase, Shotaro ^{[1
]}

Yagi, Kiyohito ^{[1
]}

Kondoh, Masuo ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan

来源：

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 2014年 / 134卷 / 05期

关键词：

claudin; tight junction; epithelium; drug development; TIGHT JUNCTION STRANDS; CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; CLAUDINS; OCCLUDIN; BARRIER; CANCER; ABSORPTION; TRANSPORT; PROTEINS; THERAPY;

D O I：

10.1248/yakushi.14-00006-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epithelium plays pivotal roles in biological barrier separating the inside of body and the outside environment. Ninety percent of malignant tumors are derived from epithelium. Most pathological microorganisms invade into the body from mucosal epithelium. Thus, epithelium is potential targets for drug development. Claudins (CLs), a family of tetra-transmembrane protein consisting of over 20 members, are structural and functional components of tight junction-seals in epithelium. Modulation of CL-seals enhanced mucosal absorption of drugs. CLs are often over-expressed in malignant tumors. CL-4 expression is increased in the epithelial cells covering the mucosal immune tissues. Very recently, CLs are also expected to be targets for traumatic brain injury and regenerative therapy. In this review, we overview the past, the present and the future of CLs-targeted drug development.

引用

页码：641 / 645

页数：5

共 32 条

[1]

Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO

[2]

2-J

[3] Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury [J].